GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shortwave Life Sciences PLC (AQSE:PSY) » Definitions » Insider Ownership

Shortwave Life Sciences (AQSE:PSY) Insider Ownership : 0.00 % (As of Apr. 27, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Shortwave Life Sciences Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Shortwave Life Sciences's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Shortwave Life Sciences's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Shortwave Life Sciences's Float Percentage Of Total Shares Outstanding is N/A.


Shortwave Life Sciences Insider Ownership Historical Data

The historical data trend for Shortwave Life Sciences's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shortwave Life Sciences Insider Ownership Chart

Shortwave Life Sciences Annual Data
Trend
Insider Ownership

Shortwave Life Sciences Semi-Annual Data
Insider Ownership

Shortwave Life Sciences Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Shortwave Life Sciences Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
17 Hanover Square, London, GBR, W1S 1BN
Shortwave Life Sciences PLC is a biopharmaceutical company focused in advancing pioneering therapies in mental health care, also it is involved in developing novel drug combinations and delivery methods to treat patients suffering from mental health disorders. It identifies, operates and creates value from early-stage, breakthrough initiatives, with an initial focus on eating disorders.

Shortwave Life Sciences Headlines